Senate Democrats seek to create federal agency for drug cost control

Sens. Cory Booker, D-N.J., and Bernie Sanders, I-Vt., both Democratic presidential hopefuls, introduced a bill Nov. 15 that would create a federal Bureau of Prescription Drug Affordability and Access to regulate drug prices, The Hill reports. 

Advertisement

The bill was sponsored by another candidate for president, Sen. Kamala Harris, D-Calif., according to the report. 

If passed, the agency would regulate prices set by pharmaceutical companies, and it would have the authority to end exclusivity protections on drugs if companies do not set fair prices, according to the report. The House is voting next month on a bill that would authorize Medicare to negotiate drug prices. 

Read more here

 

More articles on leadership and management:

Moody’s chief economist: Numbers check out on Warren’s ‘Medicare for All’ funding plan
Are you a CEO with anxiety, depression? You’re not alone
Former Microsoft exec to chair advisory board for University of Washington’s Population Health Initiative

At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Leadership & Management

Advertisement

Comments are closed.